Telos Capital Management Inc. Has $6.97 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Telos Capital Management Inc. grew its holdings in Edwards Lifesciences Co. (NYSE:EW - Free Report) by 158.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 91,405 shares of the medical research company's stock after purchasing an additional 56,000 shares during the period. Telos Capital Management Inc.'s holdings in Edwards Lifesciences were worth $6,970,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in EW. Vanguard Group Inc. boosted its stake in shares of Edwards Lifesciences by 0.6% during the 3rd quarter. Vanguard Group Inc. now owns 51,633,416 shares of the medical research company's stock valued at $3,577,163,000 after buying an additional 325,808 shares during the period. Alliancebernstein L.P. boosted its position in Edwards Lifesciences by 0.3% during the second quarter. Alliancebernstein L.P. now owns 20,512,235 shares of the medical research company's stock valued at $1,934,919,000 after purchasing an additional 66,763 shares during the last quarter. Wellington Management Group LLP grew its stake in Edwards Lifesciences by 9.2% in the third quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company's stock valued at $1,138,575,000 after purchasing an additional 1,390,427 shares in the last quarter. Moneta Group Investment Advisors LLC increased its position in Edwards Lifesciences by 104,971.3% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 15,399,249 shares of the medical research company's stock worth $1,148,938,000 after purchasing an additional 15,384,593 shares during the last quarter. Finally, Brown Advisory Inc. raised its stake in shares of Edwards Lifesciences by 5.7% during the 3rd quarter. Brown Advisory Inc. now owns 15,133,146 shares of the medical research company's stock worth $1,048,424,000 after purchasing an additional 818,849 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 7,255 shares of the company's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the sale, the chief financial officer now owns 19,248 shares of the company's stock, valued at $1,506,925.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $92.32, for a total transaction of $1,329,408.00. Following the completion of the sale, the vice president now owns 173,849 shares in the company, valued at approximately $16,049,739.68. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the business's stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total transaction of $567,993.95. Following the completion of the transaction, the chief financial officer now owns 19,248 shares in the company, valued at $1,506,925.92. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 194,004 shares of company stock worth $17,166,254. 1.27% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms recently commented on EW. Wells Fargo & Company upgraded Edwards Lifesciences from an "equal weight" rating to an "overweight" rating and set a $94.00 price objective on the stock in a report on Friday, February 2nd. Mizuho upped their price objective on shares of Edwards Lifesciences from $95.00 to $105.00 and gave the stock a "buy" rating in a report on Thursday, April 11th. Stifel Nicolaus raised their target price on Edwards Lifesciences from $70.00 to $83.00 and gave the company a "hold" rating in a report on Wednesday, February 7th. Oppenheimer upped their price target on Edwards Lifesciences from $93.00 to $100.00 and gave the stock an "outperform" rating in a research note on Monday, March 18th. Finally, Royal Bank of Canada increased their price objective on Edwards Lifesciences from $95.00 to $101.00 and gave the company an "outperform" rating in a report on Monday. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and an average price target of $91.73.

Edwards Lifesciences Stock Performance

Shares of NYSE:EW traded down $2.81 on Wednesday, hitting $87.24. 2,877,656 shares of the company were exchanged, compared to its average volume of 3,875,281. The company's 50 day moving average price is $90.11 and its two-hundred day moving average price is $78.07. The firm has a market capitalization of $52.51 billion, a price-to-earnings ratio of 39.16, a PEG ratio of 4.42 and a beta of 1.05. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.40 and a current ratio of 3.38. Edwards Lifesciences Co. has a one year low of $60.57 and a one year high of $96.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Tuesday, February 6th. The medical research company reported $0.64 earnings per share for the quarter, hitting analysts' consensus estimates of $0.64. The business had revenue of $1.53 billion for the quarter, compared to the consensus estimate of $1.50 billion. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The firm's revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the business earned $0.64 earnings per share. Research analysts expect that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.